Zhongxing Liao
University of Texas M D Anderson Cancer Center, USA
Posters & Accepted Abstracts: J Nucl Med Radiat Ther
Preclinical and epidemiologic studies suggest that receipt of cardiac and anti -hypertensive medications such as angiotensinconverting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), �²-blockers, or aspirin may have antiproliferative effects in several types of cancer. We have performed a series of studies aiming at estimating survival outcomes in patients receiving incidental cardiovascular medications during treatment for lung cancer, and to compare outcomes with those patients not receiving these medications. The retrospective study was approved by our institutional review board and informed consents were wavered. The study included 673 patients who had received definitive radiotherapy for stage III non-small-cell lung cancer (NSCLC) at our department. Cox proportional hazard models were used to assess associations between receipt of ACEIs, ARBs, �²-blockers, or aspirin and locoregional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). Multivariate analyses showed that ACEI receipt was associated with poorer LRPFS but had no effect on DMFS, DFS, or OS. Aspirin receipt was associated only with improved DMFS, and �²-blocker receipt was associated with improved DMFS, DFS, and OS. Incidental receipt of ACEIs was associated with a higher prevalence of local failure, whereas receipt of either �²-blockers or aspirin had protective effects on survival outcomes in this large group of patients with lung cancer. This finding warrants further clinical and preclinical exploration, as it may have important implications for treating patients with lung cancer who are also receiving cardiac medications.
Email: zliao@mdanderson.org
Nuclear Medicine & Radiation Therapy received 706 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 